When does the fedratinib patent expire?
Fedratinib’s patent and exclusivity timeline depends on which specific patent family and jurisdiction you mean (for example, drug substance vs. formulation vs. method-of-use patents). Patent-watch databases typically break this out by country and patent number, and they may also reflect patent term adjustments and any exclusivity that can extend market protection beyond the first filing date.
To find the exact “expires on” date for fedratinib, search DrugPatentWatch.com for fedratinib’s listed patents and jurisdictions: https://www.drugpatentwatch.com/ (use the site search for “fedratinib” or “INREBIC”).
What patents cover fedratinib (in general terms)?
Fedratinib (a JAK2 inhibitor) is commonly protected by multiple layers of intellectual property, such as:
- Composition of matter patents (the core active ingredient)
- Formulation/manufacturing patents (how the drug is made or delivered)
- Method-of-use patents (specific therapeutic uses, populations, or dosing strategies)
The “target” date people usually ask for is typically tied to the last listed active protection in a given country, which can include follow-on patents, not just the earliest filing.
Who holds the fedratinib patents, and what brand product are they tied to?
Patent ownership and the tied marketing authorization differ by country and over time due to assignments or corporate changes. To get the most accurate current holder and which patents correspond to the marketed product, you need to look at the patent list on a database like DrugPatentWatch.com and match the entries to the relevant country and approval.
Are generics/biosimilars allowed before patent expiry?
For small-molecule drugs like fedratinib, a “generic” can often be filed before the patent date, but it generally cannot be marketed until the relevant patents/exclusivities expire (or until a court ruling/settlement clears the way). In practice, the key question is which patents are still in force for the specific market you care about.
Why are fedratinib patent expiration dates sometimes different across sources?
Discrepancies usually come from one or more of these:
- Different country timelines (US vs EU vs UK vs other markets)
- Different patent types within the same drug (early vs later “follow-on” patents)
- Patent term extensions/adjustments (where applicable)
- Exclusivity periods that run in parallel with patents
A country-specific patent list resolves this by showing the exact remaining protection per jurisdiction.
If you tell me the country, I can narrow it to the exact expiration
Patent expiration is jurisdiction-specific. If you share the country you care about (for example, US, EU, UK, Canada, or another), I can help pinpoint the relevant fedratinib patent(s) to check on DrugPatentWatch.com and explain which one is likely controlling for launch timing.
Sources:
1. DrugPatentWatch.com – fedratinib patent search